BioAtla/$BCAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Ticker
$BCAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
61
ISIN
US09077B1044
Website
BioAtla Metrics
BasicAdvanced
$28M
-
-$1.21
1.00
-
Price and volume
Market cap
$28M
Beta
1
52-week high
$2.19
52-week low
$0.24
Average daily volume
566K
Financial strength
Current ratio
2.345
Quick ratio
2.022
Total debt to equity
101.28
Management effectiveness
Return on assets (TTM)
-65.79%
Return on equity (TTM)
-246.21%
Valuation
Price to revenue (TTM)
2.239
Price to book
51.45
Price to tangible book (TTM)
51.45
Price to free cash flow (TTM)
-0.429
Growth
Earnings per share change (TTM)
-51.36%
3-year revenue growth (CAGR)
253.03%
3-year earnings per share growth (CAGR)
-24.79%
What the Analysts think about BioAtla
Analyst ratings (Buy, Hold, Sell) for BioAtla stock.
BioAtla Financial Performance
Revenues and expenses
BioAtla Earnings Performance
Company profitability
BioAtla News
AllArticlesVideos
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
GlobeNewsWire·1 month ago
BioAtla to Participate in the Citizens Life Sciences Conference
GlobeNewsWire·1 month ago
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioAtla stock?
BioAtla (BCAB) has a market cap of $28M as of June 09, 2025.
What is the P/E ratio for BioAtla stock?
The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of June 09, 2025.
Does BioAtla stock pay dividends?
No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of June 09, 2025.
When is the next BioAtla dividend payment date?
BioAtla (BCAB) stock does not pay dividends to its shareholders.
What is the beta indicator for BioAtla?
BioAtla (BCAB) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.